The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Carl Borrebaeck

Carl Borrebaeck

Professor

Carl Borrebaeck

Detection of pancreatic cancer using antibody microarray-based serum protein profiling

Author

  • Johan Ingvarsson
  • Christer Wingren
  • Anders Carlsson
  • Peter Ellmark
  • Britta Wahren
  • Gunilla Engström
  • Ulrika Harmenberg
  • Morten Krogh
  • Carsten Peterson
  • Carl Borrebaeck

Summary, in English

The driving force behind oncoproteomics is to identify protein signatures that are associated with a particular malignancy. Here, we have used a recombinant scFv antibody microarray in an attempt to classify sera derived from pancreatic adenocarcinoma patients versus healthy subjects. Based on analysis of nonfractionated, directly labeled, whole human serum proteomes we have identified a protein signature based on 19 nonredundant analytes, that discriminates between cancer patients and healthy subjects. Furthermore, a potential protein signature, consisting of 21 protein analytes, could be defined that was shown to be associated with cancer patients having a life expectancy of <12 months. Taken together, the data suggest that antibody microarray analysis of complex proteomes will be a useful tool to define disease associated protein signatures.

Department/s

  • Department of Immunotechnology
  • Computational Biology and Biological Physics - Undergoing reorganization

Publishing year

2008

Language

English

Pages

2211-2219

Publication/Series

Proteomics

Volume

8

Issue

11

Document type

Journal article

Publisher

John Wiley & Sons Inc.

Topic

  • Immunology in the medical area
  • Biophysics

Status

Published

ISBN/ISSN/Other

  • ISSN: 1615-9861